| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Anti-inflammatory agent 36 targets inflammatory pathways, reducing the release of inflammatory mediators. It inhibits LPS-induced macrophage activation. It exhibits dose-dependent inhibition of LPS-induced release of TNF-α and IL-6 in activated RAW 264.7 mouse macrophages with IC50 values of 3.69 μM and 3.68 μM, respectively.
|
|---|---|
| ln Vitro |
Anti-inflammatory agent 36 (Compound 5a28) has an IC50 of 3.69 μM for TNF-α and 3.68 μM for IL-6, which inhibits the release of both cytokines from activated RAW 264.7 murine macrophages when exposed to LPS[1]. In RAW 264.7 murine macrophages, LPS-induced P-P38 and P-ERK is inhibited by anti-inflammatory drug 36 (10 μM, 0.5 hours)[1]. Anti-inflammatory drug 36 (10 μM, 0.5 h) suppresses TNF-α, IL-6, IL-1β, ICAM-1, and VCAM-1 transcription that is triggered by LPS [1].
In vitro, Anti-inflammatory agent 36 inhibits LPS-induced macrophage activation. It shows dose-dependent inhibition of TNF-α (IC50 = 3.69 μM) and IL-6 (IC50 = 3.68 μM) release in RAW 264.7 mouse macrophages. It suppresses the NF-κB signaling pathway. |
| ln Vivo |
In a mouse model of acute lung injury, anti-inflammatory drug 36 (compound 5a28) (10 mg/kg, intraperitoneal injection) reduces inflammation[1].
In vivo, Anti-inflammatory agent 36 has potential anti-inflammatory effects based on its in vitro activity. Animal studies are needed to confirm its in vivo efficacy and safety. Its suppression of inflammatory mediators suggests potential for treating inflammatory diseases. |
| Enzyme Assay |
Cell-free assays for Anti-inflammatory agent 36: anti-inflammatory activity is assessed by measuring inhibition of NF-κB activation or cytokine production in cell-free systems. The compound is incubated with components of the NF-κB pathway, and activity is measured. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: RAW 264.7 mouse macrophages Tested Concentrations: 10 μM Incubation Duration: 0.5 h Experimental Results: Markedly inhibited P-P38 and P-ERK, indicating the suppression of MAPK signaling. Cellular assays for Anti-inflammatory agent 36: RAW 264.7 mouse macrophages are cultured and treated with Anti-inflammatory agent 36 at concentrations of 0.1-100 µM for 1-24 hours, then stimulated with LPS. TNF-α and IL-6 levels in the culture medium are measured by ELISA. NF-κB activation is assessed by Western blot or reporter gene assays. Cell viability is assessed by MTT assay. |
| Animal Protocol |
Animal/Disease Models: Acute lung injury mouse model[1]
Doses: 10 mg/kg Route of Administration: ip Experimental Results: decreased wet/dry weight ratio of the mice lungs. decreased biomarkers of lymphocytes and macrophages. Suppresses TNF-α, IL-6, IL -1β, 7 VACM-1 and ICAM-1 levels. In vivo animal studies for Anti-inflammatory agent 36: animal models of inflammation (e.g., LPS-induced endotoxemia, carrageenan-induced paw edema) would be used. Animals are administered Anti-inflammatory agent 36 orally or intraperitoneally at doses of 1-10 mg/kg. Inflammatory cytokine levels, edema, and other inflammatory markers are assessed. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Anti-inflammatory agent 36: as a small molecule (molecular weight 453.48), it may have moderate oral bioavailability. It is likely metabolized in the liver and excreted via the kidneys. Detailed PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicity of Anti-inflammatory agent 36: comprehensive toxicity data are limited. It is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Qian J, et al. Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI). Eur J Med Chem. 2019 Apr 1;167:414-425.
|
| Additional Infomation |
Anti-inflammatory agent 36 is a research compound with potential applications in anti-inflammatory research. It is a small-molecule inhibitor of inflammatory signaling pathways. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C25H27NO7
|
|---|---|
| Molecular Weight |
453.48
|
| Exact Mass |
453.178
|
| CAS # |
2293951-01-4
|
| PubChem CID |
155521683
|
| Appearance |
White to yellow solid powder
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
722
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1OC)OC)/C=C/2\CCCN(C2=O)C(=O)/C=C/C3=CC(=C(C=C3)O)OC
|
| InChi Key |
XQUXWWVMQPNGGF-KWKAUDIHSA-N
|
| InChi Code |
InChI=1S/C25H27NO7/c1-30-20-13-16(7-9-19(20)27)8-10-23(28)26-11-5-6-18(25(26)29)12-17-14-21(31-2)24(33-4)22(15-17)32-3/h7-10,12-15,27H,5-6,11H2,1-4H3/b10-8+,18-12+
|
| Chemical Name |
(3E)-1-[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-3-[(3,4,5-trimethoxyphenyl)methylidene]piperidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (55.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2052 mL | 11.0258 mL | 22.0517 mL | |
| 5 mM | 0.4410 mL | 2.2052 mL | 4.4103 mL | |
| 10 mM | 0.2205 mL | 1.1026 mL | 2.2052 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
